Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

References

• Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1115–1140. ix. doi:10.1016/j.hoc.2007.08.010.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23:2210–2221. doi:10.1038/leu.2009.174.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. doi:10.3322/caac.21332.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–1076. doi:10.1182/blood-2012-01-405985.
   PubMed Web of Science ®Google Scholar
• Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat. 2017;8:268. doi:10.1038/s41467-017-00296-y.
   Google Scholar
• Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, et al. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007;317–323.
   Google Scholar
• Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22:231–239. doi:10.1038/sj.leu.2405016.
   PubMed Web of Science ®Google Scholar
• Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482–488. doi:10.1309/74R4-TB90-BUWH-27JX.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Lam CM, Lee HC. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci Signal. 2012;5:ra67. doi:10.1126/scisignal.2003289.
   PubMed Web of Science ®Google Scholar
• Lee HC. Structure and enzymatic functions of human CD38. Mol Med. 2006;12:317–323. doi:10.2119/2006–00086.Lee.
   PubMed Web of Science ®Google Scholar
• Hubert S, Rissiek B, Klages K, Huehn J, Sparwasser T, Haag F, et al. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med. 2010;207:2561–2568. doi:10.1084/jem.20091154.
   PubMed Web of Science ®Google Scholar
• Karakasheva TA, Waldron TJ, Eruslanov E, Kim SB, Lee JS, O’Brien S, et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res. 2015;75:4074–4085. doi:10.1158/0008-5472.CAN-14-3639.
   PubMed Web of Science ®Google Scholar
• Rissiek B, Haag F, Boyer O, Koch-Nolte F, Adriouch S. ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. Curr Top Microbiol Immunol. 2015;384:107–126. doi:10.1007/82_2014_420.
   PubMed Web of Science ®Google Scholar
• Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci. 2015;1335:10–22. doi:10.1111/nyas.12485.
   PubMed Web of Science ®Google Scholar
• Ghose J, Terrazas C, Viola D, Caserta E, Krishnan A, Hofmeister CC, et al. Daratumumab impairs myeloma cell adhesion mediated drug resistance through CD38 internalization. Blood. 2016;128:abstract#4479. doi:10.1182/blood-2016-06-724161.
   Web of Science ®Google Scholar
• Funaro A, Reinis M, Trubiani O, Santi S, Di Primio R, Malavasi F. CD38 functions are regulated through an internalization step. J Immunol. 1998;160:2238–2247.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mallone R, Baj G, Arnulfo A, Surico N, Dianzani U, et al. CD38/CD31, a receptor/ligand system ruling adhesion and signaling in human leukocytes. Chem Immunol. 2000;75:99–120.
   PubMedGoogle Scholar
• Van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13–29. doi:10.1182/blood-2017-06-740944.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331. doi:10.1056/NEJMoa1607751.
   PubMed Web of Science ®Google Scholar
• Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128:1821–1828. doi:10.1182/blood-2016-07-726729.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766. doi:10.1056/NEJMoa1606038.
   PubMed Web of Science ®Google Scholar
• Rajan AM, Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J. 2016;6:e451. doi:10.1038/bcj.2016.53.
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207–1219. doi:10.1056/NEJMoa1506348.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518–528. doi:10.1056/NEJMoa1714678.
   PubMed Web of Science ®Google Scholar
• Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015;6:120–127. doi:10.1177/2040620715572295.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, Van Egmond M, Lammerts Van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. mAbs. 2015;7:311–321. doi:10.1080/19420862.2015.1007813.
   PubMed Web of Science ®Google Scholar
• Markovina S, Callander NS, O’Connor SL, Xu G, Shi Y, Leith CP, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010;9:176. doi:10.1186/1476-4598-9-254.
   PubMed Web of Science ®Google Scholar
• Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood. 2007;110:4373–4384. doi:10.1182/blood-2006-07-038026.
   PubMed Web of Science ®Google Scholar
• Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech. 2012;5:763–771. doi:10.1242/dmm.008961.
   PubMed Web of Science ®Google Scholar
• Gastelum G, Kraut J, Poteshkina A, Artiga E, Weckstein G, Frost P. Targeting of the hypoxia-induced acid microenvironment of multiple myeloma cells increases hypoxia-mediated apoptosis. Blood. 2017;130:abstract#4376.
   Web of Science ®Google Scholar
• Orciani M, Trubiani O, Guarnieri S, Ferrero E, Di Primio R. CD38 is constitutively expressed in the nucleus of human hematopoietic cells. J Cell Biochem. 2008;105:905–912. doi:10.1002/jcb.21887.
   PubMed Web of Science ®Google Scholar
• Jackson DG, Bell JI. Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J Immunol. 1990;144:2811–2815.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Park KS, Jeon IS, Choi JW, Lee SJ, Choy HE, et al. LAMP-3 (Lysosome-Associated Membrane Protein 3) promotes the intracellular proliferation of Salmonella typhimurium. Mol Cells. 2016;39:566–572. doi:10.14348/molcells.2016.0112.
   PubMed Web of Science ®Google Scholar
• WHt H, Szymanski CJ, Payne CK. Endo-lysosomal vesicles positive for Rab7 and LAMP1 are terminal vesicles for the transport of dextran. PloS One. 2011;6:e26626. doi:10.1371/journal.pone.0026626.
   PubMed Web of Science ®Google Scholar
• Kirchhausen T, Macia E, Pelish HE. Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol. 2008;438:77–93. doi:10.1016/S0076-6879(07)38006-3.
   PubMed Web of Science ®Google Scholar
• Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget; 2013. 2186–2207.
   Google Scholar
• Di Marzo L, Desantis V, Solimando AG, Ruggieri S, Annese T, Nico B, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7:60698–60711. doi:10.18632/oncotarget.10849.
   PubMed Web of Science ®Google Scholar
• Van der Veer MS, De Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96:284–290. doi:10.3324/haematol.2010.030759.
   PubMed Web of Science ®Google Scholar
• Wang X, Ottosson A, Ji C, Feng X, Nordenskjold M, Henter JI, et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica. 2009;94:470–478. doi:10.3324/haematol.13783.
   PubMed Web of Science ®Google Scholar
• Feng X, Yan J, Wang Y, Zierath JR, Nordenskjold M, Henter JI, et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol. 2010;47:2388–2396. doi:10.1016/j.molimm.2010.05.003.
   PubMed Web of Science ®Google Scholar
• Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, DiPersio J, et al. 2017. Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med.
   PubMed Web of Science ®Google Scholar
• Caserta E, Chea J, Minnix M, Viola D, Vonderfecht S, Yazaki P, et al. Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018. doi:10.1182/blood-2017-09-807263.
   PubMedGoogle Scholar
• Green DJ, O’Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018;131:611–620. doi:10.1182/blood-2017-09-807610.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–1767. doi:10.3324/haematol.2012.065698.
   PubMed Web of Science ®Google Scholar
• Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant. 2013;48:10–18. doi:10.1038/bmt.2012.26.
   PubMed Web of Science ®Google Scholar
• Pelekanos Ra, Ting Mj, Sardesai Vs, Ryan Jm, Lim Yc, Chan Jk, et al. Intracellular trafficking and endocytosis of CXCR4 in fetal mesenchymal stem/stromal cells. BMC Cell Biol. 2014;15:15. doi:10.1186/1471-2121-15-15.
   PubMed Web of Science ®Google Scholar
• Chaffey N, Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular biology of the cell. 4thedn. Annals of Botany. 2003;91:401. doi:10.1093/aob/mcg023.
   Google Scholar
• Alberts B. Molecular biology of the cell; 2002. New York: Garland Science.
   Google Scholar
• An G, Jiang H, Acharya C, Zhong MY, Cai T, Yang G, et al. SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma. Blood. 2014;124:4729.
   Web of Science ®Google Scholar
• Tonino SH, Spijker R, Luijks DM, van Oers MH, Kater AP. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. Blood. 2008;112:840–843. doi:10.1182/blood-2008-03-144576.
   PubMed Web of Science ®Google Scholar
• Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, et al. CD38 and bone marrow microenvironment. Front Biosci (Landmark Ed). 2014;19:152–162.
   PubMed Web of Science ®Google Scholar
• Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology. 2013;2:e26246. doi:10.4161/onci.26246.
   PubMed Web of Science ®Google Scholar
• Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, et al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+. Oncoimmunology; 2018. e1458809.
   Google Scholar
• Funaro A, De Monte LB, Dianzani U, Forni M, Human MF. CD38 is associated to distinct molecules which mediate transmembrane signaling in different lineages. Eur J Immunol. 1993;23:2407–2411. doi:10.1002/eji.1830231005.
   PubMed Web of Science ®Google Scholar
• Kuemmerle JF, Makhlouf GM. Agonist-stimulated cyclic ADP ribose. Endogenous modulator of Ca(2+)-induced Ca2+ release in intestinal longitudinal muscle. J Biol Chem. 1995;270:25488–25494.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U, et al. Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood. 2002;99:2490–2498.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, et al. Fratricide of NK cells in Daratumumab therapy for multiple myeloma overcome by ex vivo expanded autologous NK Cells. Clin Cancer Res. 2018. doi:10.1158/1078-0432.ccr-17-3117.
   Web of Science ®Google Scholar
• Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget. 2014;5:5686–5699. doi:10.18632/oncotarget.2159.
   PubMed Web of Science ®Google Scholar
• Malavasi F, Chillemi A, Castella B, Schiavoni I, Incarnato D, Oliva S, et al. CD38 and antibody therapy: what can basic science add?Blood. 2016;128:SCI–36.
   Google Scholar
• Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, et al. NAD(+)-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells. 2015;4:520–537. doi:10.3390/cells4030520.
   PubMed Web of Science ®Google Scholar
• Chillemi A, Quarona V, Antonioli L, Ferrari D, Horenstein AL, Malavasi F. Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche. Front Immunol. 2017;8:305. doi:10.3389/fimmu.2017.00305.
   PubMed Web of Science ®Google Scholar
• Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, et al. Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. Oncotarget. 2017;8:56598–56611. doi:10.18632/oncotarget.17896.
   PubMedGoogle Scholar
• Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, 3rd, Armand P, et al. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1737–1743. doi:10.1016/j.bbmt.2014.06.040.
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, et al. A Bortezomib-based regimen offers promising survival and graft-versus-host disease Prophylaxis in Myeloablative HLA-mismatched and unrelated donor transplantation: a phase II Trial. Biol Blood Marrow Transplant. 2015;21:1907–1913. doi:10.1016/j.bbmt.2015.05.027.
   PubMed Web of Science ®Google Scholar
• Terrazas C, Oghumu S, Varikuti S, Martinez-Saucedo D, Beverley SM, Satoskar AR. Uncovering Leishmania-macrophage interplay using imaging flow cytometry. J Immunol Methods. 2015;423:93–98. doi:10.1016/j.jim.2015.04.022.
   PubMed Web of Science ®Google Scholar
• Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, et al. Histone deacetylase inhibitors enhance the therapeutic potential of Reovirus in multiple myeloma. Mol Cancer Ther. 2016;15:830–841. doi:10.1158/1535-7163.MCT-15-0240-T.
   PubMed Web of Science ®Google Scholar
• Newton AJ, Kirchhausen T, Murthy VN. Inhibition of dynamin completely blocks compensatory synaptic vesicle endocytosis. Proc Natl Aca Sci U S A. 2006;103:17955–17960. doi:10.1073/pnas.0606212103.
   PubMed Web of Science ®Google Scholar